Additionally, Western blot results also showed that the expression levels of CyclinD1 and Bcl-2 were downregulated, while Bax expression was upregulated in all three types of GBM cells after treatment (Fig. 5C–F). The gene discussed is BCL2; the disease is glioblastoma.